ACEA Therapeutics

ACEA Therapeutics, o lo'o i San Diego, Kalefonia ose lala atoa a Sorrento. ACEA Therapeutics ua tuuto atu i le atinaʻeina ma le tuʻuina atu o togafitiga fou e faʻaleleia ai olaga o tagata mamaʻi o loʻo maua i faʻamaʻi e lamatia ai le ola.

O le matou taʻitaʻi, Abivertinib, o se tamaʻi mole kinase inhibitor, o loʻo iloiloina nei e le China Food and Drug Administration (CFDA) mo togafitiga o tagata mamaʻi e le o ni tamaʻi kanesa mama (NSCLC) o loʻo iai le suiga o le EGFR T790M. O loʻo iai foʻi i faʻataʻitaʻiga faʻataʻitaʻiga e togafitia ai tagata gasegase ile falemaʻi ma Covid-19 i Pasila ma US taʻitaʻia e Sorrento Therapeutics. Ole fa'atosina mole kinase lona lua ole ACEA, AC0058, ua ulufale ile Vaega 1B atina'e ile US mo togafitiga ole systemic lupus erythematosus (SLE).

Faatasi ai ma se faalapotopotoga malosi R&D, ua faatuina e le ACEA le gaosiga o fualaau faasaina ma gafatia faapisinisi i Saina e lagolago ai lo tatou tuputupu ae umi. O nei atina'e ua maua ai e i matou le pule sili atu i la matou sapalai filifili ina ia mautinoa o oloa e avatu i gasegase i le taimi.

SILEX

SCILEX HOLDING COMPANY ("Scilex") , o se lala o le tele o lo'o umia e Sorrento, e fa'amaoni i le atina'eina ma le fa'atauina o oloa e pulea ai tiga. Le oloa ta'imua a le kamupani ZTlido^® (lidocaine topical system 1.8%), o se fa'ailoga fa'aigoaina o le lidocaine topical product ua fa'amaonia e le US Food and Drug Administration mo le fa'amaloloina o tiga e feso'ota'i ma le Post-Herpetic Neuralgia (PHN), o se ituaiga o tiga neura pe a uma le shingles.

Scilex's SP-102 (10 mg dexamethasone sodium phosphate gel), poʻo SEMDEXA ™, mo le togafitiga o Lumbar Radicular Pain o loʻo i ai i le faagasologa o le faʻamaeʻaina o le Vaega III faʻataʻitaʻiga falemaʻi. O loʻo faʻamoemoe le kamupani SP-102 e avea ma faʻataʻitaʻiga muamua a le FDA e le faʻatagaina epidural tui e togafitia ai le tiga o le radicular lumbosacral, poʻo le sciatica, faatasi ai ma le gafatia e sui ai le 10 i le 11 miliona tui faʻamaʻi epidural steroid e faʻatautaia i tausaga taʻitasi i le US.

Bioserv

Bioserv, o loʻo i San Diego, Kalefonia o se lala atoa a Sorrento. Fa'atūina i le 1988, o le fa'alapotopotoga o se ta'ita'i o le cGMP e tu'uina atu auaunaga fa'akonekarate ma sili atu i le 35,000 sikuea mita o fale o lo'o fa'atotonugalemu le agava'a autu i le fa'aogaina o le tele o le aseptic ma le non-aseptic; fa'amama; fa'atumu; taofi; auaunaga lyophilization; fa'ailoga; fa'aputuga o oloa mae'a; pusa ma afifiina; fa'apea fo'i ma le fa'atonuina o le teuina o le vevela ma le tufatufaina atu o auaunaga e lagolago ai Pre-Clinical, Phase I ma II Clinical Trial vaila'au, mea fa'afoma'i masini fa'afoma'i, vaila'au fa'afoma'i fa'ama'i ma pusa, ma mea fa'asaienisi ola.

Concortis-Levena

I le 2008, na fa'atūina ai le Concortis Biosystems ma le fa'amoemoe e sili atu le tautuaina o le sosaiete fa'asaienisi ma vaila'au fa'atasi ai ma le maualuga o le antibody drug conjugate (ADC) reagents ma auaunaga. I le 2013, na maua ai e Sorrento Concortis, fatuina o se kamupani maualuga ADC. O le tu'ufa'atasiga o le G-MAB ™ (le faletusi atoa o tagata antibody) fa'atasi ai ma le Concortis proprietary toxin, feso'ota'iga, ma auala fa'atasi e mafai ona fa'atupuina ai le ta'ita'iina o pisinisi, 3rd generation ADCs.

Concortis o loʻo suʻesuʻeina nei i luga ole 20 filifiliga ADC eseese (muaʻi-maʻi) faʻatasi ai ma talosaga ile oncology ma tua atu. O Oketopa 19, 2015, Sorrento faʻasalalau le faʻavaeina o Levena Biopharma o se faʻalapotopotoga tutoʻatasi e ofoina atu i le maketi se lautele lautele o auaunaga ADC mai le amataga o se poloketi ADC e ala i le gaosiga o le cGMP o ADCs i le vaega I / II suʻesuʻega falemaʻi. Mo fa'amatalaga auiliili, fa'amolemole asiasi www.levenabiopharma.com

SmartPharm Therapeutics, Inc

SmartPharm Therapeutics, Inc. (“SmartPharm”), ose lala e pulea atoa e Sorrento Therapeutics, Inc. (Nasdaq: SRNE), o se atinaʻe tulaga biopharmaceutical kamupani taulai atu i le isi augatupulaga, non-viral gene togafitiga mo le togafitia o faamaʻi ogaoga pe seasea ma le vaaiga o le fatuina o "biologics mai totonu." SmartPharm o loʻo fausia nei se tala, DNA-encoded monoclonal antibody e puipuia ai faʻamaʻi pipisi i le SARS-CoV-2, le siama e mafua ai le COVID-19 i lalo o se konekarate ma le Defense Advanced Research Projects Agency a le US Department of Defense. SmartPharm na amata fa'agaioiga i le 2018 ma o lo'o fa'auluulu i Cambridge, MA, ISA.

Soifua Maloloina o Manu

Ark Animal Health ose lala e pulea atoa e Sorrento. Na fausia le Atolaau i le 2014 e aumai i le soa maketi manu ni fofo fou na tuuina mai mai suesuega faaletagata ma gaoioiga atinae a Sorrento. O lo'o fa'atulagaina ina ia avea ma fa'alapotopotoga tuto'atasi atoatoa ma fa'atututoatasi pe a o'o atu i tulaga fa'apisinisi (oloa ua sauni e maua le faamaoniga a le FDA).

Polokalama atina'e ta'ita'i a Ark (ARK-001) o se vaifofo tui tui fa'ama'i e tasi le resiniferatoxin (RTX). Ua maua e le ARK-001 le FDA CVM (Center for Veterinary Medicine) MUMS (faʻaoga laiti / laiti ituaiga) faʻailoga mo le puleaina o tiga o le kanesa o ponaivi i taifau. O isi galuega faatino e aofia ai faʻamatalaga faaopoopo mo le RTX i vaega e pei o le tiga faʻamaʻi masani i manu faʻatasi, tiga o le neuropathic i solofanua, ma le cystitis idiopathic i pusi, faʻapea foʻi ma le suʻesuʻeina o avanoa atinaʻe i le vaega o faʻamaʻi pipisi poʻo togafitiga o le kanesa.

VirexHealth